{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T19:25:23Z","timestamp":1777145123141,"version":"3.51.4"},"reference-count":27,"publisher":"Bentham Science Publishers Ltd.","issue":"2","funder":[{"DOI":"10.13039\/501100004320","name":"Shiraz University of Medical Sciences","doi-asserted-by":"publisher","award":["5900"],"award-info":[{"award-number":["5900"]}],"id":[{"id":"10.13039\/501100004320","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRR"],"published-print":{"date-parts":[[2020,5,11]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Systemic sclerosis (SSc) is a systematic and rare autoimmune disease that affects many organs. N-acetylcysteine (NAC), thiol-containing compound, can act both as the precursor of reduced glutathione and direct scavenger of reactive oxygen species.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>We assessed the clinical effect of NAC on the pulmonary function test of patients with diffuse scleroderma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>This study is a randomized double-blind clinical trial that was done on 25 patients with diffuse SSc without lung involvement on primary chest high-resolution computed tomography. Placebo was administered for 13 patients and 1200 milligram NAC for 12 patients. Body plethysmography parameters were assessed at the beginning of the study and after 24 weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Patients in the two groups were matched in the basic demographic data like age, duration of disease, and modified Rodnan skin score. The analysis showed no significant differences in parameters of plethysmography between the two groups. After importing the data of 2 patients in the placebo-treated group, who developed interstitial lung disease, DLCO in the placebo-treated group was 90.69 \u00b1 21.29 milliliter at the end of the study, which significantly decreased compared with the beginning of the study (102.30 \u00b1 13.83 ml). Also, changes of DLCO between the two groups were significantly different.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>In this trial, the sensitivity of DLCO as the first marker in the evaluation of pulmonary function in patients with SSc was confirmed. On the other hand, NAC had no effect versus placebo in a period of 24 weeks.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1573397115666191212092608","type":"journal-article","created":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T06:11:31Z","timestamp":1576217491000},"page":"149-157","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effects of N-acetylcysteine on Pulmonary Functions in Patients with Systemic Sclerosis: A Randomized Double Blind, Placebo Controlled Study"],"prefix":"10.2174","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8231-7815","authenticated-orcid":true,"given":"Samrad","family":"Mehrabi","sequence":"first","affiliation":[{"name":"Division of Pulmonology, Department of Internal Medicine, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam M.","family":"Moradi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4876-4312","authenticated-orcid":true,"given":"Zohre","family":"Khodamoradi","sequence":"additional","affiliation":[{"name":"Student Research Committee, Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2045-2958","authenticated-orcid":true,"given":"Mohammad A.","family":"Nazarinia","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.rbr.2014.07.001","volume":"54","author":"Correa M.J.U.","year":"2014","unstructured":"Correa M.J.U.; Mariz H.A.; Andrade L.E.C.; Kayser C.; [Oral N-acetylcysteine in the treatment of Raynaud\u2019s phenomenon secondary to systemic sclerosis: a randomized, double-blind, placebo-controlled clinical trial]. Rev Bras Reumatol 2014,54(6),452-458","journal-title":"Rev Bras Reumatol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1001\/jama.2014.6368","volume":"311","author":"van Laar J.M.","year":"2014","unstructured":"van Laar J.M.; Farge D.; Sont J.K.; Naraghi K.; Marjanovic Z.; Larghero J.; Schuerwegh A.J.; Marijt E.W.; Vonk M.C.; Schattenberg A.V.; Matucci-Cerinic M.; Voskuyl A.E.; van de Loosdrecht A.A.; Daikeler T.; K\u00f6tter I.; Schmalzing M.; Martin T.; Lioure B.; Weiner S.M.; Kreuter A.; Deligny C.; Durand J.M.; Emery P.; Machold K.P.; Sarrot-Reynauld F.; Warnatz K.; Adoue D.F.; Constans J.; Tony H.P.; Del Papa N.; Fassas A.; Himsel A.; Launay D.; Lo Monaco A.; Philippe P.; Qu\u00e9r\u00e9 I.; Rich \u00c9.; Westhovens R.; Griffiths B.; Saccardi R.; van den Hoogen F.H.; Fibbe W.E.; Soci\u00e9 G.; Gratwohl A.; Tyndall A.; EBMT\/EULAR Scleroderma Study Group.Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014,311(24),2490-2498","journal-title":"JAMA"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/s13075-015-0872-2","volume":"17","author":"Khanna D.","year":"2015","unstructured":"Khanna D.; Nagaraja V.; Tseng C.H.; Abtin F.; Suh R.; Kim G.; Wells A.; Furst D.E.; Clements P.J.; Roth M.D.; Tashkin D.P.; Goldin J.; Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials. Arthritis Res Ther 2015,17(1),372","journal-title":"Arthritis Res Ther"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1002\/art.38702","volume":"66","author":"Herzog E.L.","year":"2014","unstructured":"Herzog E.L.; Mathur A.; Tager A.M.; Feghali-Bostwick C.; Schneider F.; Varga J.; Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct? Arthritis Rheumatol 2014,66(8),1967-1978","journal-title":"Arthritis Rheumatol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.autrev.2016.01.007","volume":"15","author":"Desbois A.C.","year":"2016","unstructured":"Desbois A.C.; Cacoub P.; Systemic sclerosis: An update in 2016. Autoimmun Rev 2016,15(5),417-426","journal-title":"Autoimmun Rev"},{"key":"ref=6","author":"Yousif M.","year":"2014","unstructured":"Yousif M.; Habib R.; Esaely H.; Yasin R.; Sonbol A.; Interleukin-6 in systemic sclerosis and potential correlation with pulmonary involvement.European Respiratory Journal. SHEFFIELD S10 2PX, ENGLAND: EUROPEAN RESPIRATORY SOC JOURNALS LTD 2014"},{"key":"ref=7","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00005512","author":"Solomon J.J.","year":"2013","unstructured":"Solomon J.J.; Olson A.L.; Fischer A.; Bull T.; Brown K.K.; Raghu G.; Scleroderma lung disease 2013","journal-title":"Scleroderma lung disease"},{"key":"ref=8","author":"Tyndall A.J.","year":"2010","unstructured":"Tyndall A.J.; Bannert B.; Vonk M.; Air\u00f2 P.; Cozzi F.; Carreira P.E.; Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database Annals of the rheumatic diseases 2010"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.berh.2009.12.002","volume":"24","author":"Khanna D.","year":"2010","unstructured":"Khanna D.; Denton C.P.; Evidence-based management of rapidly progressing systemic sclerosis. Best Pract Res Clin Rheumatol 2010,24(3),387-400","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1002\/1529-0131(200011)43:11<2437:AID-ANR10>3.0.CO;2-U","volume":"43","author":"Steen V.D.","year":"2000","unstructured":"Steen V.D.; Medsger T.A.; Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000,43(11),2437-2444","journal-title":"Arthritis Rheum"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"R144","DOI":"10.1186\/ar4606","volume":"16","author":"Fraticelli P.","year":"2014","unstructured":"Fraticelli P.; Gabrielli B.; Pomponio G.; Valentini G.; Bosello S.; Riboldi P.; Gerosa M.; Faggioli P.; Giacomelli R.; Del Papa N.; Gerli R.; Lunardi C.; Bombardieri S.; Malorni W.; Corvetta A.; Moroncini G.; Gabrielli A.; Imatinib in Scleroderma Italian Study Group.Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Res Ther 2014,16(4),R144","journal-title":"Arthritis Res Ther"},{"key":"ref=12","author":"Joven B.E.","year":"2010","unstructured":"Joven B.E.; Almodovar R.; Carmona L.; Carreira P.E.; Survival, causes of death, and risk factors associated with mortality in Spanish systemic sclerosis patients: results from a single university hospital Seminars in arthritis and rheumatism 2010","journal-title":"Survival, causes of death, and risk factors associated with mortality in Spanish systemic sclerosis patients: results from a single university hospital Seminars in arthritis and rheumatism"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1002\/1529-0131(199912)42:12<2660:AID-ANR23>3.0.CO;2-N","volume":"42","author":"Bryan C.","year":"1999","unstructured":"Bryan C.; Knight C.; Black C.M.; Silman A.J.; Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum 1999,42(12),2660-2665","journal-title":"Arthritis Rheum"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","volume":"177","author":"Goh N.S.","year":"2008","unstructured":"Goh N.S.; Desai S.R.; Veeraraghavan S.; Hansell D.M.; Copley S.J.; Maher T.M.; Corte T.J.; Sander C.R.; Ratoff J.; Devaraj A.; Bozovic G.; Denton C.P.; Black C.M.; du Bois R.M.; Wells A.U.; Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008,177(11),1248-1254","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=15","author":"Tay T.","year":"2017","unstructured":"Tay T.; Ferdowsi N.; Baron M.; Stevens W.; Hudson M.; Proudman S.M.; Measures of disease status in systemic sclerosis: A systematic review Seminars in arthritis and rheumatism 2017","journal-title":"Measures of disease status in systemic sclerosis: A systematic review Seminars in arthritis and rheumatism"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1164\/ajrccm.156.6.9706065","volume":"156","author":"Behr J.","year":"1997","unstructured":"Behr J.; Maier K.; Degenkolb B.; Krombach F.; Vogelmeier C.; Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med 1997,156(6),1897-1901","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S1734-1140(10)70250-4","volume":"62","author":"Radomska-Le\u015bniewska D.M.","year":"2010","unstructured":"Radomska-Le\u015bniewska D.M.; Skopi\u0144ska-R\u00f3zewska E.; Jankowska-Steifer E.; Sobiecka M.; Sadowska A.M.; Hevelke A.; Malejczyk J.; N-acetylcysteine inhibits IL-8 and MMP-9 release and ICAM-1 expression by bronchoalveolar cells from interstitial lung disease patients. Pharmacol Rep 2010,62(1),131-138","journal-title":"Pharmacol Rep"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1055\/s-0030-1256592","volume":"65","author":"Gillissen A.","year":"2011","unstructured":"Gillissen A.; [Anti-inflammatory efficacy of N-acetylcysteine and therapeutic usefulness]. Pneumologie 2011,65(9),549-557","journal-title":"Pneumologie"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","volume":"366","author":"Raghu G.","year":"2012","unstructured":"Raghu G.; Anstrom K.J.; King T.E.; Lasky J.A.; Martinez F.J.; Idiopathic Pulmonary Fibrosis Clinical Research Network.Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012,366(21),1968-1977","journal-title":"N Engl J Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/resp.12477","volume":"20","author":"Sakamoto S.","year":"2015","unstructured":"Sakamoto S.; Muramatsu Y.; Satoh K.; Ishida F.; Kikuchi N.; Sano G.; Sugino K.; Isobe K.; Takai Y.; Homma S.; Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study. Respirology 2015,20(3),445-452","journal-title":"Respirology"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"van den Hoogen F.","year":"2013","unstructured":"van den Hoogen F.; Khanna D.; Fransen J.; Johnson S.R.; Baron M.; Tyndall A.; Matucci-Cerinic M.; Naden R.P.; Medsger T.A.; Carreira P.E.; Riemekasten G.; Clements P.J.; Denton C.P.; Distler O.; Allanore Y.; Furst D.E.; Gabrielli A.; Mayes M.D.; van Laar J.M.; Seibold J.R.; Czirjak L.; Steen V.D.; Inanc M.; Kowal-Bielecka O.; M\u00fcller-Ladner U.; Valentini G.; Veale D.J.; Vonk M.C.; Walker U.A.; Chung L.; Collier D.H.; Csuka M.E.; Fessler B.J.; Guiducci S.; Herrick A.; Hsu V.M.; Jimenez S.; Kahaleh B.; Merkel P.A.; Sierakowski S.; Silver R.M.; Simms R.W.; Varga J.; Pope J.E.; 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013,65(11),2737-2747","journal-title":"Arthritis Rheum"},{"key":"ref=22","doi-asserted-by":"publisher","DOI":"10.4172\/2161-1149.S1-003","author":"Assayag D","year":"2012","unstructured":"Assayag D; Kaduri S; Hudson M; Hirsch A; Baron M; High resolution computed tomography scoring systems for evaluating interstitial lung disease in systemic sclerosis patients. Rheumatology: Current Research 2012"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1136\/ard.38.4.356","volume":"38","author":"Furst D.E.","year":"1979","unstructured":"Furst D.E.; Clements P.J.; Harris R.; Ross M.; Levy J.; Paulus H.E.; Measurement of clinical change in progressive systemic sclerosis: a 1 year double-blind placebo-controlled trial of N-acetylcysteine. Ann Rheum Dis 1979,38(4),356-361","journal-title":"Ann Rheum Dis"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1056\/NEJMoa042976","volume":"353","author":"Demedts M.","year":"2005","unstructured":"Demedts M.; Behr J.; Buhl R.; Costabel U.; Dekhuijzen R.; Jansen H.M.; MacNee W.; Thomeer M.; Wallaert B.; Laurent F.; Nicholson A.G.; Verbeken E.K.; Verschakelen J.; Flower C.D.; Capron F.; Petruzzelli S.; De Vuyst P.; van den Bosch J.M.; Rodriguez-Becerra E.; Corvasce G.; Lankhorst I.; Sardina M.; Montanari M.; IFIGENIA Study Group.High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005,353(21),2229-2242","journal-title":"N Engl J Med"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.2169\/internalmedicine.49.4011","volume":"49","author":"Bando M.","year":"2010","unstructured":"Bando M.; Hosono T.; Mato N.; Nakaya T.; Yamasawa H.; Ohno S.; Sugiyama Y.; Long-term efficacy of inhaled N-acetylcysteine in patients with idiopathic pulmonary fibrosis. Intern Med 2010,49(21),2289-2296","journal-title":"Intern Med"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1183\/09031936.93.02020116","volume":"2","author":"Wagner P.D.","year":"1989","unstructured":"Wagner P.D.; Mathieu-Costello O.; Bebout D.E.; Gray A.T.; Natterson P.D.; Glennow C.; Protection against pulmonary O2 toxicity by N-acetylcysteine. Eur Respir J 1989,2(2),116-126","journal-title":"Eur Respir J"},{"key":"ref=27","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00283.200","author":"Wolters P.J.","year":"2009","unstructured":"Wolters P.J.; Could N-acetylcysteine slow progression of idiopathic pulmonary fibrosis by inhibiting EMT? 2009","journal-title":"Could N-acetylcysteine slow progression of idiopathic pulmonary fibrosis by inhibiting EMT?"}],"container-title":["Current Rheumatology Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/177374","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T23:15:03Z","timestamp":1695510903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/177374\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,11]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,5,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573397115666191212092608","relation":{},"ISSN":["1573-3971"],"issn-type":[{"value":"1573-3971","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-06-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}